Recently appointed as general manager & vice president of Gilead’s UK and Ireland operations, Hilary Hutton-Squire highlights the uniqueness of the UK’s healthcare system, its expertise in life sciences and global leadership in clinical trials. To her, the UK has to maintain its core differentiators, such as a health technology assessment system that truly appraises value when deciding upon reimbursement and investment.
Hilary, you have very recently been appointed as general manager of Gilead in the UK. What have been the priorities that were laid out for your tenure?
"It is Gilead’s mission to develop innovative treatments in areas of high unmet need. Nobody comes to work in a pharma company wanting to develop a ‘me too’ medicine - everyone wants to find a cure for cancer."
